Bone disease Articles
-
Peptides for Osteoporosis Research
Introduction to OsteoporosisOsteoporosis is a systemic multi-causal skeletal disease that is prone to fractures due to changes in systemic bone mass and microstructure of bone tissue, resulting in increased bone fragility. Osteoporosis is a type of disease that is difficult to cure. According to the etiology, it can be divided into primary osteoporosis, secondary osteoporosis and idiopathic ...
By BOC Sciences
-
Sacral Insufficiency Fractures in a Geriatric Patient Treatment with the Curvafix IM System - Case Study
CASE PRESENTATION A 70-year-old female had a ground-level fall. Computed tomography imaging showed sacral insufficiency fractures in the left ala. No lumbar fracture was observed. Conservative treatment was initiated but the patient was referred 6 weeks post injury, unable to mobilize with a walker and needing a wheelchair. There was no anterior pelvic pain with palpation or weight bearing, but ...
-
“Y” Shaped Sacral Fragility Fracture Treatment with the Curvafix IM System - Case Study
CASE PRESENTATION A 68-year-old female with some dysmorphism and mild osteoporosis had a fall in the shower, resulting in a Y-shaped sacral fracture and non-displaced fractures of the superior and inferior pubic ...
-
Rani is Opening Doors in Biosimilars, Challenging Humira and Others
San Jose-based Rani Therapeutics reported its fourth quarter and full-year 2021 financial results, as well as several corporate updates. The company hit major milestones this year, including the recent launch of the RaniPill High Capacity, which opens doors for significant developments in biosimilars. Rani has been on the radar of major life science investors for years. The company caught ...
-
Treatment of Traumatic Shin Wound using CDO Therapy - Case study
Patient: 72 year old female with a traumatic wound on left shin Age of Wound: 180 days Medical History: Altered mental/mobility, dementia, aphasia, anxiety, tremors, HTN, osteoporosis, A Fib, edema Previous Treatment: Moist wound therapy, TenderWet®, Aquacel®, Santyl® Treatment: OxyGeni® set at 5-8 ml/hr using an OxySpur® Diffusion Dressing Days on Service: 77 days ...
By EO2 Concepts
-
Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual-Energy X-Ray Absorptiometry (DXA)
ABSTRACT Previous subgroup analyses from the ACTIVE trial in women with postmenopausal osteoporosis (NCT01343004) using three-dimensional (3D)-processing of dual X-ray absorptiometry (DXA) scans indicated greater increases in total hip cortical volumetric bone mineral density (Ct.vBMD) and estimated indices of hip strength following 18 months of abaloparatide (ABL) versus placebo or ...
-
Rani developing technology for oral delivery of injectable biologics
(NASDAQ:RANI) is developing a disruptive technology to solve the problem of converting biologic injectable drugs, including antibodies, peptides and proteins, into oral therapies with its RaniPill that bypasses destruction in the stomach to deliver its payload to the vascular intestinal wall in the GI tract. “This is not a new idea, although previous attempts were based on chemistry and ...
-
Design and R&D of Covalent Drugs
For a long time, electrophilic groups have been a minefield in drug development. Therefore, in the classic medicinal chemistry textbooks of the past, it is always recommended to avoid introducing functional groups such as epoxide, acridine and Michael receptor into the structure of drug molecules, because these functional groups are highly reactive and may interact with a wide range of biological ...
By BOC Sciences
-
Rani Therapeutics’ $73M IPO will fund upcoming clinical trials
Rani Therapeutics, a San Jose-based company developing a pill to replace medical injections, went public on Friday. According to S-1 filings, shares were estimated to price between $14 and $16 last week. On Friday, shares debuted slightly lower, around $11. Rani raised about $73 million in its debut. Rani’s debut comes amidst a flurry of IPO activity in therapeutics. In 2020, 71 ...
-
Rani Therapeutics offers breakthrough capsule for patients with chronic conditions
Rani Therapeutics offers a breakthrough capsule, the RaniPill which could change the way patients with chronic conditions take medication by eliminating the need for painful injections. Rani Therapeutics is a clinical-stage biotherapeutics company offering an alternative to painful injections for patients with chronic conditions such as neuroendocrine tumours(NETS). The company based in ...
-
Rani Therapeutics Debuts on the Nasdaq: What uou should know About the Biopharma
IMPORTANT MESSAGE: Benzinga prides itself as a media platform that is "For the People, By the People." We understand the markets are scary right now. For that reason, we are here to help. For today only get access to our #1 Options Newsletter for only $1. Rani Therapeutics Holdings, Inc. RANI+ Free Alerts, a San Jose, California-based early stage biopharma, debuted Friday on the Nasdaq ...
-
Rani Therapeutics prices $73M IPO for robotic drug-delivery pill tech
Rani Therapeutics Holdings (NSDQ:RANI), developer of a robotic drug-delivery pill system, generated $73.3 million in its underwritten initial public offering (IPO) of Class A common stock. The San Jose, Calif.–based company’s IPO of 6.7 million shares priced at $11 a share, generating gross proceeds of $73.3 million. The company initially targeted an IPO worth approximately $100 ...
-
Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling
Abstract In postmenopausal osteoporotic women in ACTIVE, abaloparatide reduced fracture risk and increased areal bone mineral density (BMD) more than teriparatide at the hip and wrist. DXA-based 3D modeling showed significantly greater increases in hip cortical volumetric BMD with abaloparatide versus teriparatide. This may explain differences reported in aBMD by DXA. Introduction: In ...
-
Effects of supervised high-intensity resistance and impact training or machine-based isometric training on regional bone geometry and strength in middle-aged and older men with low bone mass: The LIFTMOR-M semi-randomised controlled trial
Abstract Introduction: Few data exist on the effects of bone-targeted exercise on geometric and biomechanical indices of bone strength in men. The Lifting Intervention For Training Muscle and Osteoporosis Rehabilitation for Men (LIFTMOR-M) trial was designed to compare the efficacy and safety of two novel, supervised, twice-weekly, high-intensity exercise programs in middle-aged and older ...
-
Could more sunshine make you less anxious?
It is no surprise that basking in sunshine can do a lot to improve your mood, but do you know about the link between vitamin D and mental health? Sunlight is the best source of vitamin D, which we need to enable our bodies to convert the calcium in our diets to strengthen our bones. In addition to maintaining good bone health, vitamin D has been linked with many other physiological functions in ...
-
Effect of combined Low-Dose Radon- and Hyperthermia Treatment (LDRnHT) of patients with ankylosing spondylitis on serum levels of cytokines and bone metabolism markers: a pilot study
Ankylosing Spondylitis (AS) is a rheumatic disease and almost 50% of the affected patients suffer from osteoporosis. The ratio of Receptor Activator of Nuclear Factor κB Ligand (RANKL) and Osteoprotegerin (OPG) has become an important marker to assess the status of systemic bone metabolism and has been shown to be dysregulated in AS patients. Combined Low-Dose Radon- and Hyperthermia Therapy ...
-
Analysisof alendronicacidin pharmaceutical formulations
Alendronic acid or Alendronate Sodium is a bisphosphonate drug that inhibits osteoclast-mediated bone resorption. Biphosphates work by binding to the bone and preventing calcium from being removed by osteoclasts. This drug is used to prevent and treat osteoporosis as well as several other bone diseases. Alendronate Sodium is sold as tablets or solutions, alone or in combination with Vitamin D. ...
-
Impact of feeding flaxseed oil on delaying the development of osteoporosis in ovariectomised diabetic rats
This work is aimed to study the effect of diabetes on bone health and to evaluate the impact of feeding flaxseed oil on delaying osteoporosis. About 70 female albino rats were included; 30 were ovariectomised (ovx). Experimental diabetes was induced. Rats were classified in groups as control, sham, diabetic, diabetic received flaxseed oil in the diet, ovx, ovx-diabetic and ovx-diabetic received ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you